A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia

Inclusion Criteria: * Patients with mild to moderate primary hypercholesterolemia with stabilized LDL-C baseline ≥130 mg/dL and ≤ 250 mg/dL (≥ 3.36 mmol/L and ≤ 6.46 mmol/L) * Male aged ≥ 18 years or postmenopausal women at screening Exclusion Criteria: * Presence of any clinically significant endocrine disease known to influence serum lipids or lipoproteins * Patients with type 1 diabetes * Presence or history of cancer within the past five years * Triglycerides ≥ 300 mg/dL (3.39 mmol/L) * Fasting plasma glucose \> 160 mg/dL (8.9 mmol/L) * Impaired kidney function and active liver disease * Within one month prior to screening visit and/or at the time or after the screening visit, administration of any lipid lowering treatment * Creatine Kinase \> 2xUpper Limit of Normal range The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.